AGI: Enough with the hype; let’s ask the important questions
Today’s horse-race coverage of artificial general intelligence fails to consider its implications.
Discover industry-specific solutions and expertise.
Solve your toughest A&D challenges with Belcan.
Ignite peak performance and efficiency in your business.
Reimagine your manufacturing competitive advantage.
Accelerate growth with customer-focused solutions.
Our data and AI solutions align with your business outcomes and create impactful results.
Personalize learning experiences with education tech and IT solutions—and make learners feel valued.
Create strategies for product, service and process innovation that deliver new growth.
Meet customer demands for a digital, personalized online insurance experience—while reducing risk.
Digitally transform to empower a more intelligent, agile and high-performing enterprise.
Make business decisions based on real-time contextual data with our digital solutions.
Stay ahead of the competition with the latest tech like IoT, machine learning and blockchain.
Deep industry expertise to propel your business into the future.
Explore Belcan’s flexible, custom-tailored solutions.
Put AI to work and turn opportunity into value.
Accelerate time to value for industrial edge AI.
Maintain high integrity across the AI lifecycle.
Realize the next frontier of enterprise performance.
Enhance operations, boost efficiency, remove technical debt and modernize apps for the future.
Operate with insight and speed—using AI-powered processes that supercharge performance.
Boost operational efficiency, optimize costs and speed product development.
Reimagine the customer experience, attract and retain top talent, and win in the digital economy.
Sense change, optimize operations and mitigate risk with data-driven insights at quantum speed.
Enable a more secure and value-centered business with proven next-gen solutions.
AI insights to inspire enterprise transformation.
Understand and anticipate the needs of AI-empowered customers.
Invest in people to unlock the power of AI.
Bridge the gap between strong AI leadership and business readiness.
Explore the future of business with our Gen AI insights.
Explore the top focus areas that are important to Cognizant and our clients.
Dive into our forward-thinking research and uncover new tech and industry trends.
Check out our other insights and research—and the experts behind them.
Explore how our expertise can help you sense opportunities sooner and outpace change.
Discover industry-specific solutions and expertise.
Solve your toughest A&D challenges with Belcan.
Ignite peak performance and efficiency in your business.
Reimagine your manufacturing competitive advantage.
Accelerate growth with customer-focused solutions.
Our data and AI solutions align with your business outcomes and create impactful results.
Personalize learning experiences with education tech and IT solutions—and make learners feel valued.
Create strategies for product, service and process innovation that deliver new growth.
Meet customer demands for a digital, personalized online insurance experience—while reducing risk.
Digitally transform to empower a more intelligent, agile and high-performing enterprise.
Make business decisions based on real-time contextual data with our digital solutions.
Stay ahead of the competition with the latest tech like IoT, machine learning and blockchain.
Deep industry expertise to propel your business into the future.
Explore Belcan’s flexible, custom-tailored solutions.
Put AI to work and turn opportunity into value.
Accelerate time to value for industrial edge AI.
Maintain high integrity across the AI lifecycle.
Realize the next frontier of enterprise performance.
Enhance operations, boost efficiency, remove technical debt and modernize apps for the future.
Operate with insight and speed—using AI-powered processes that supercharge performance.
Turn big visions into practical realities with expertise that takes you further.
Boost operational efficiency, optimize costs and speed product development.
Reimagine the customer experience, attract and retain top talent, and win in the digital economy.
Sense change, optimize operations and mitigate risk with data-driven insights at quantum speed.
Enable a more secure and value-centered business with proven next-gen solutions.
Turn sustainability commitments into achievable milestones.
AI insights to inspire enterprise transformation.
Understand and anticipate the needs of AI-empowered customers.
Invest in people to unlock the power of AI.
Bridge the gap between strong AI leadership and business readiness.
Explore the future of business with our Gen AI insights.
Keep up with the trends shaping the future of business—and stay ahead in a fast-changing world.
Explore the top focus areas that are important to Cognizant and our clients.
Dive into our forward-thinking research and uncover new tech and industry trends.
Check out our other insights and research—and the experts behind them.
Explore how our expertise can help you sense opportunities sooner and outpace change.
October 27, 2023
By changing their approach to clinical development with generative AI, life sciences companies can realize exponential revenue opportunities and offer renewed hope to patients.
When it comes to clinical development, saving time translates to saving lives, or at least improving them, through faster availability of treatments. For life sciences companies, it also translates into revenue opportunity—and a significant one at that. Some industry sources estimate that delivering new treatments to market ahead of schedule can be worth anywhere from $600,000 to $8 million per day.
The promise of speed is why generative AI is so compelling for life sciences companies. Generative AI helps automate standard development processes, find patterns, identify insights and produce relevant, meaningful content in any number of formats, all in a fraction of the time it would take for a human to do so.
We’ve identified four key areas of the clinical development lifecycle that can be accelerated and enhanced through the use of generative AI and supporting technologies. For life sciences companies that adopt gen AI, clinical development efficiency gains will be measured not in days or weeks but in months or even years—representing both an exponential revenue opportunity and renewed hope for patients.
#1: Streamline research processes using semantic search. Generative AI could fundamentally change the clinical and scientific research process. Instead of beginning with a manual keyword search and sifting through hundreds of articles across various sources, research teams could prompt a generative AI-enabled tool to rapidly search, gather and distill relevant articles or even suggest unanticipated information pathways to explore. This frees researchers to focus on analysis.
In our client engagements, we’ve seen 10X time savings when life sciences companies have applied generative AI to the research process.
Generative AI could also change how research is conducted. Because the underlying models understand intent and context, these tools can work from a mission- or goal-based prompt, as opposed to relying on traditional keyword searches.
For example, if a company is developing a cholesterol medication, a traditional process might begin with keyword searches involving different combinations of terms like "cholesterol," "clinical trial,” "efficacy," "safety," "hyperlipidemia" and "statins," ultimately uncovering disparate results across different source platforms.
However, with an AI-enabled tool, researchers could state their goal and receive contextualized reference materials to support that specific concept. “I'm designing a clinical trial for a new cholesterol medication,” a researcher might state to a generative AI tool. “Please provide an overview of the most recent studies on cholesterol medications, their efficacy and safety, and how they compare with existing treatments. Also, any insights on best practices and regulations would be valuable."
Finally, generative AI can also be used to analyze and synthesize relevant research materials and present them in a digestible way to a variety of constituents, from team members across multiple departments, to regulatory agencies, to institutional and ethical review boards. Ideally, these summaries would include a high degree of explainability regarding why those materials were selected. This further expedites the review process, which can also unlock time savings.
Explainability is the ability of the generative AI-enabled tool to document how it arrived at the conclusions presented in a given output and provide a rationale for any recommendations being proposed.
For example, when authoring a clinical trial protocol, the tool may include references to past protocols in a government database with similar trial dynamics, as well as components from successful trials.
This capability can help researchers and other team members quickly assess the output, view it within the proper context and identify the best next step in the process.
#2: Automate the authoring of clinical trial protocols to improve efficiency and access. It can take a few months to over a year to author a clinical trial protocol document. But companies that leverage generative AI and large language models (LLMs) can dramatically reduce that time, to days or even hours.
A foundational model for research can be fed and trained on thousands of clinical trial protocols available online through government and industry databases and proprietary company research data. As such, generative AI-enabled tools can quickly scan thousands of entries within a given database and identify the patterns relevant to investigational products, certain conditions, specific patient populations or other factors. If the company has its own proprietary data, the tool can also incorporate that information into the foundational research model.
As the tool identifies relevant patterns, it can design a baseline study, define the narrative, determine eligibility, draft exclusionary criteria and provide other details. The draft, or a group of draft options, can then be evaluated and refined by a human.
It’s also possible to expedite the protocol review and approval cycles because the protocol could be summarized and accompanied by an explanation. We estimate that life sciences companies can shave 50% to 60% off the time spent writing protocols, while reducing related review cycles another 10% to 20%.
Life sciences companies can also use generative AI to design studies that leverage other digital capabilities or enable a non-traditional trial model, such as a decentralized, virtual or hybrid format.
For example, during the authoring phase, the foundational model or LLM could leverage valid data from wearables, sensors or other means of collecting biomarkers outside of a traditional clinical trial site or clinical setting. When they have specific information about the technologies needed to enable such a trial, companies can consider a wider range of options, which may, in turn, allow them to recruit from a larger base of participants.
In this way, generative AI isn’t just expediting the authoring process, but potentially designing a trial format that would speed recruitment, enrollment and testing.
Beyond identifying eligible trial participants, generative AI could also analyze demographic and behavioral data to suggest population segments likely to use these tools and remain engaged throughout the study.
#3: Identify areas for improvement through next-gen clinical study reports. It’s very time-consuming to analyze clinical trial data and summarize it in a way that demonstrates statistical significance, while also maintaining safety and efficacy standards. It’s also prone to error when done manually.
For years, conventional AI has been used to accelerate this compilation of data through prediction and probability. However, generative AI can reveal new connections not immediately apparent to human researchers or conventional models.
For example, traditional AI may be able to extract a key statistic, such as trial recruitment velocity. However, with generative AI, the model could explain the reason behind that number and also offer recommendations for improvement.
The additional context and recommendations could include:
One of the major value drivers of generative AI is that this information is all conveyed in an easy-to-understand format. No longer would research teams need to review several pages of Excel-based data or perform manual calculations to see how changes in the strategy may affect outcomes. Nor would they need to cross-reference data with social media plans or ad buys. Instead, the tool takes all that information and consolidates it into a clear list of recommended actions.
#4: Expedite the treatment launch process. Once approval for a new therapy is secured in a primary market, a tremendous amount of work goes into launching the drug in a secondary market. This includes strategy development, market research, contracting, pharmacy benefit manager (PBM) negotiations, agency engagement, content creation and material development. As with the research and protocol writing processes, much of this activity could be automated through generative AI. And, as noted above, gen AI-enabled tools can also provide recommended actions to improve outcomes or further accelerate the process.
We estimate that companies could generate another 10X time savings, compared with traditional processes, through the use of gen AI in this area. For example, when a drug is close to gaining approval, generative AI can help commercial teams research and compile baseline strategy documents for secondary markets, taking into account any specific regulations that need to be adhered to.
In addition, generative AI-enabled tools can be used to translate existing materials, such as ads, websites, brochures or other sales materials, so that these assets reflect the local language and culture. Using the technology in this way could shed an additional year from the go-to-market timeline and dramatically reduce costs related to content creation and design across various markets.
While generative AI will undoubtedly play a role in the future of the life sciences industry, factors such as an uncertain regulatory landscape, coupled with the rapidly evolving nature of generative AI itself, are prompting some companies to delay investment until the course ahead is clearer.
However, those who take a strategic approach at this early juncture and build maturity will likely find themselves with a strong competitive advantage as the rest of the industry plays catchup.
With that in mind, here are six recommendations for building generative AI maturity today:
Most of the use cases explored here are relatively straightforward, both in terms of their practicality and low barriers to deployment. They represent a low-risk, high-reward value proposition.
However, far more advanced use cases represent the next generation of this technology, such as using generative AI-enabled telehealth tools for patient companion apps. These applications, which would mimic a traditional caregiver experience and provide one-on-one patient support, present a tremendous opportunity to improve access to care, while also addressing significant shortages of healthcare professionals.
As life sciences companies experiment with generative AI, they will begin to lay the foundation needed to harness its full potential for both their own business and the people they serve.
To learn more, visit the Generative AI and Life Sciences sections of our website or contact us.
Today’s horse-race coverage of artificial general intelligence fails to consider its implications.
As agentic AI systems continue to evolve, they will become an indispensable part of the modern financial infrastructure.
In-store retail is enjoying a renaissance—and with it, familiar challenges. Judicious use of AI in retail can help businesses thrive in this new era.
Edge AI is a crucial step for AI-connected living. It also introduces challenges that telecoms and original design manufacturers need to be wary of to thrive in the era to come.
Traditional encryption methods are at risk of being broken by quantum computers. Here’s how organizations can adopt post quantum solutions to protect their digital communications and data.
Sign up for the Cognizant newsletter to gain actionable AI advice and real-world business insights delivered to your inbox every month.